Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 08, 2013
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Journal: Journal of the National Cancer Institute
Published: December 06, 2011
Showing 1-4 of 4
Last Updated: 09/26/2026